Essais liés13clinical trials
VilleMontreallocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06782490

Ouvrir le site du centre

Essais cliniques associés

13
MoléculeIndication / populationPhaseNCTTitreStatut
Prasinezumab Parkinson Phase 2 NCT04777331 PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease ACTIVE_NOT_RECRUITING
BMS-986368 Myopathies Phase 2 NCT06782490 MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity RECRUITING
Prasinezumab Parkinson Phase 3 NCT07174310 PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease RECRUITING
MT-1186 Sclérose latérale amyotrophique Phase 3 NCT04165824 Safety Study of Oral Edaravone Administered in Subjects With ALS COMPLETED
MT-1186 Sclérose latérale amyotrophique Phase 3 NCT04577404 Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) COMPLETED
ALN-SOD Sclérose latérale amyotrophique Phase 1/2 NCT06351592 GOALS — First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) RECRUITING
Ocrelizumab SEP Phase 3 NCT05269004 OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis ACTIVE_NOT_RECRUITING
RO7121932 IV SEP Phase 1 NCT05704361 A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis ACTIVE_NOT_RECRUITING
Fosigotifator Sclérose latérale amyotrophique Phase 1 NCT04948645 A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis TERMINATED
MT-1186 Sclérose latérale amyotrophique Phase 3 NCT04569084 Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS TERMINATED
Interferon beta-1a SEP Phase 3 NCT01412333 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis COMPLETED
Ocrelizumab SEP Phase 3 NCT01194570 ORATORIO — A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis COMPLETED
Fenebrutinib SEP Phase 3 NCT04544449 FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis ACTIVE_NOT_RECRUITING